Protective effect of oral L-arginine administration on gentamicin-induced renal failure in rats

Can C. , Sen S. , Boztok N., Tuglular I.

EUROPEAN JOURNAL OF PHARMACOLOGY, vol.390, no.3, pp.327-334, 2000 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 390 Issue: 3
  • Publication Date: 2000
  • Doi Number: 10.1016/s0014-2999(00)00025-x
  • Page Numbers: pp.327-334


We investigated the effects of orally supplemented L-arginine, the substrate of nitric oxide (NO) and N-omega-nitro-L-arginine methyl ester (L-NAME), a nitric oxide-synthase inhibitor in gentamicin-induced renal failure. Rats were given gentamicin (100 mg/kg/day s.c.), gentamicin and L-arginine (2 g/l, drinking water), gentamicin and L-NAME (100 mg/l, drinking water) or gentamicin plus L-arginine and L-NAME. After 8 days, the gentamicin group developed marked renal failure, characterized by a significantly decreased creatinine clearance and increased blood creatinine, fractional excretion of sodium, fractional excretion of lithium, urine gamma glutamyl transferase, systolic blood pressure and daily urine volume when compared to controls. Renal histological analysis confirmed tubular necrosis. L-arginine administration caused normalization of these parameters, whereas L-NAME led to aggravation of the failure. Concomittant administration of L-NAME and L-arginine to gentamicin-treated rats caused no significant changes when compared to the rats receiving gentamicin alone. We conclude that L-arginine supplementation has beneficial effects in gentamicin-induced renal failure in rats and that these effects are reversed by the NO-synthase inhibitor, L-NAME. (C) 2000 Elsevier Science B.V. All rights reserved.